Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Status:
Terminated
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
In this study, patients who have metastatic prostate cancer that does not respond to hormone
treatment and who have mutations in certain cancer-related genes will be treated with
docetaxel and carboplatin chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Seattle Institute for Biomedical and Clinical Research
Collaborators:
Prostate Cancer Foundation VA Puget Sound Health Care System